JP2004500037A5 - - Google Patents

Download PDF

Info

Publication number
JP2004500037A5
JP2004500037A5 JP2001521746A JP2001521746A JP2004500037A5 JP 2004500037 A5 JP2004500037 A5 JP 2004500037A5 JP 2001521746 A JP2001521746 A JP 2001521746A JP 2001521746 A JP2001521746 A JP 2001521746A JP 2004500037 A5 JP2004500037 A5 JP 2004500037A5
Authority
JP
Japan
Prior art keywords
fgf
polypeptide
seq
nucleic acid
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001521746A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004500037A (ja
Filing date
Publication date
Priority claimed from PCT/US1999/020594 external-priority patent/WO2000015666A2/en
Priority claimed from PCT/US1999/021090 external-priority patent/WO2000015796A2/en
Priority claimed from PCT/US1999/030999 external-priority patent/WO2001005836A1/en
Priority claimed from PCT/US2000/004414 external-priority patent/WO2001004311A1/en
Application filed filed Critical
Priority claimed from PCT/US2000/006471 external-priority patent/WO2001018210A1/en
Publication of JP2004500037A publication Critical patent/JP2004500037A/ja
Publication of JP2004500037A5 publication Critical patent/JP2004500037A5/ja
Withdrawn legal-status Critical Current

Links

JP2001521746A 1999-09-08 2000-03-09 繊維芽細胞成長因子−１９（ｆｇｆ−１９）核酸及びポリペプチド並びに肥満の治療のための利用の方法 Withdrawn JP2004500037A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/US1999/020594 WO2000015666A2 (en) 1998-09-10 1999-09-08 Compositions and methods for the treatment of tumors
PCT/US1999/021090 WO2000015796A2 (en) 1998-09-16 1999-09-15 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US1999/030999 WO2001005836A1 (en) 1999-07-20 1999-12-20 Polypeptidic compositions and methods for the treatment of tumors
PCT/US2000/004414 WO2001004311A1 (en) 1999-07-07 2000-02-22 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2000/006471 WO2001018210A1 (en) 1999-09-08 2000-03-09 Fibroblast growth factor-19 (fgf-19) nucleic acids and polypeptides and methods of use for the treatment of obesity

Publications (2)

Publication Number Publication Date
JP2004500037A JP2004500037A (ja) 2004-01-08
JP2004500037A5 true JP2004500037A5 (https=) 2007-05-10

Family

ID=27485920

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001521746A Withdrawn JP2004500037A (ja) 1999-09-08 2000-03-09 繊維芽細胞成長因子−１９（ｆｇｆ−１９）核酸及びポリペプチド並びに肥満の治療のための利用の方法

Country Status (7)

Country Link
EP (1) EP1214409B1 (https=)
JP (1) JP2004500037A (https=)
CN (1) CN1560249A (https=)
CA (1) CA2384089A1 (https=)
DE (1) DE60028054T2 (https=)
ES (1) ES2264929T3 (https=)
WO (1) WO2001018210A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
WO2001036640A2 (en) * 1999-11-18 2001-05-25 Chiron Corporation Human fgf-21 gene and gene expression products
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
AR035533A1 (es) 2001-01-26 2004-06-02 Schering Corp Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
US7354923B2 (en) 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
CA2462200A1 (en) 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
MXPA04002573A (es) 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
AU2003205716B2 (en) * 2002-01-31 2008-08-21 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. FGFR agonists
DE60309850T2 (de) * 2002-03-14 2007-07-05 Develogen Ag Cg8327 und srm in der regulation von energiehomeostase
MXPA04012243A (es) 2002-06-07 2005-02-25 Genentech Inc Composiciones y metodos para l diagnostico y tratamiento de tumores.
AU2003274715A1 (en) * 2002-06-10 2003-12-22 Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung L(2)44 dea, wunen-2, grapes, cg2221, cg1172, rutabaga, cg11940, facl involved in the regulation of energy homeostasis
CA2490261A1 (en) * 2002-06-27 2004-01-08 The University Of Queensland Differentiation modulating agents and uses therefor
EP1545584A4 (en) * 2002-09-18 2007-04-04 Lilly Co Eli METHOD FOR REDUCING MORBIDITY AND MORTALITY OF CRITICAL SICK PATIENTS
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
AU2003299314A1 (en) * 2002-12-16 2004-07-09 Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung Fwd, pp2c1, adk3, cg3860, cdk4, cg7134, eip75b involved in the regulation of energy homeostasis
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
EP1601668B1 (en) 2003-03-07 2008-08-27 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
CA2517572C (en) 2003-03-07 2011-12-13 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
WO2005037235A2 (en) * 2003-10-16 2005-04-28 Imclone Systems Incorporated Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
EP1989230B1 (en) 2006-02-10 2016-06-01 Genentech, Inc. Anti-fgf19 antibodies and methods using same
NZ582619A (en) 2007-08-03 2012-08-31 Genentech Inc Humanized anti-fgf19 antagonists and methods using same
WO2009046141A2 (en) 2007-10-01 2009-04-09 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
WO2012174476A2 (en) 2011-06-16 2012-12-20 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
CN113105561B (zh) 2021-04-30 2021-12-03 江南大学 一种双靶点融合蛋白的制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999014327A2 (en) * 1997-09-17 1999-03-25 Genentech, Inc. Genes amplified in tumours, antibodies against the proteins coded thereby, and their use in diagnosis and treatment of cancer
NZ503343A (en) * 1997-09-17 2002-09-27 Genentech Inc Secreted and transmembrane polypeptides and use to induce apoptosis of tumour cells
EP1032668B1 (en) * 1997-11-25 2008-05-28 Genentech, Inc. Fibroblast growth factor-19

Similar Documents

Publication Publication Date Title
JP2004500037A5 (https=)
AU776457B2 (en) Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as NGF-antagonist molecules
KR100543730B1 (ko) 종양 괴사 인자 관련 리간드
EP1012292A1 (en) Ntn-2 member of tnf ligand family
WO1998055621A1 (en) Ntn-2 member of tnf ligand family
BG65519B1 (bg) Белтъци, свързващи интерлевкин-18, тяхното получаване и приложение
CA2195955A1 (en) Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
DE69530944T2 (de) Keratinozyten-wachstumsfaktor 2
EP1019502A2 (en) Human orphan receptor ntr-1
JPH10511936A (ja) ヒトソマトスタチン様受容体
JP2005528080A5 (https=)
US6277592B1 (en) Porcine leptin protein, nucleic acid sequences coding therefor and uses thereof
US6297027B1 (en) Bovine leptin protein, nucleic acid sequences coding therefor and uses thereof
AU753400C (en) Orphan receptors
JP4307708B2 (ja) エストロゲン受容体
AU764484B2 (en) Orphan cytokine receptor
AU2004212622C1 (en) A Tumor Necrosis Factor Related Ligand
JP2002537812A5 (https=)
MXPA99001134A (en) Bovine leptin protein, nucleic acid sequences coding therefor and uses thereof
AU2007201600A1 (en) Porcine leptin protein, nucleic acid sequences coding therefor and uses thereof
AU2003257868A1 (en) Porcine Leptin Protein, Nucleic Acid Sequences Coding Therefor and Uses Thereof